MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

DVA · NYSE

DaVita Inc.

Health Care · Misc Health and Biotechnology Services

Reference price$239.46As of Jul 28, 2026
Market capitalization$15.37B
52-week range$101.00–$239.64
S&P 500 portfolio weight0.01%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$201.00-16.1% vs. reference
Average$231.80-3.2% vs. reference
High$270.00+12.8% vs. reference
2 Buy3 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportAug 4, 2026Jun 2026
Consensus EPS$4.012 estimates
Expected range$3.80–$4.22Low to high EPS
Dec 2026$15.07Street EPS consensus
Dec 2027$18.37Street EPS consensus
Dec 2028$22.91Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+6.5% YoY$13.64B$12.82B
Operating income$2.04B$2.09B
Net income$0.75B$0.94B
Operating cash flow$1.89B$2.02B
Capital expenditures($0.58B)($0.56B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

Why DaVita HealthCare (DVA) Outpaced the Stock Market Today

BNK Invest

DaVita Takes Over #492 Spot From Hormel Foods

The Motley Fool

Everyone Is Watching Greg Abel. But Another Berkshire Hathaway Stock Picker Is Quietly Winning in 2026.

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.